The survival benefit of adjuvant radiotherapy for pathological T4N2M0 colon cancer in the Modern Chemotherapy Era: evidence from the SEER database 2004–2015
| Autor: | Junfeng Chu, Wei Wei, Yong Huang, Xi Gu, Kuanxue Ge, Guangshun Fu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Oncology medicine.medical_specialty Databases Factual Colorectal cancer medicine.medical_treatment Seer database Biomedical Engineering Pharmaceutical Science Medicine (miscellaneous) Kaplan-Meier Estimate 02 engineering and technology 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Pathological Neoplasm Staging Adjuvant radiotherapy Chemotherapy business.industry Standard treatment General Medicine Middle Aged Prognosis 021001 nanoscience & nanotechnology medicine.disease Radiation therapy Survival benefit 030220 oncology & carcinogenesis Colonic Neoplasms Female Radiotherapy Adjuvant 0210 nano-technology business Biotechnology |
| Zdroj: | Artificial Cells, Nanomedicine, and Biotechnology. 48:834-840 |
| ISSN: | 2169-141X 2169-1401 |
| Popis: | Neoadjuvant chemoradiotherapy has been established as the standard treatment for patients with locally advanced rectal cancer. However, the role of radiotherapy (RT) has not been fully confirmed in advanced colon cancer (LACC). We postulated that patients with pathological T4N2 locally advanced colon cancer would benefit more from RT. 6715 pT4N2M0 colon cancer patients were included in the Surveillance, Epidemiology, and End Results (SEER) database. The primary endpoints were 5-year overall survival (OS) and cancer-specific survival (CSS). Propensity score matching (PSM) with Kaplan-Meier and Cox proportional hazards' models was performed to estimate prognosis. Before PSM, patients underwent RT had better OS and CSS as compared to patients did not receive RT (OS: 40.1% vs 27.6% |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |